Introduction
Cardiomyopathy (CM) is a disease of the heart muscle that can ultimately lead to heart failure. Despite the identification of more than 100 CM susceptibility genes, it is estimated that about one-half of human inherited CMs, particularly dilated CM (DCM), remain genetically elusive (1, 2) . Moreover, modifier genes that contribute to phenotypic variation in individual patients are largely unknown. Quantitative trait loci (QTL) mapping and GWAS have been explored in rodents, leading to the identification of modifiers such as Tnni3k and Abcc6 (3, 4) . Mutagenesis screening is a powerful forward genetic approach that has been applied to lower-model organisms, such as Drosophila, to screen genetic candidates for heart failure (5). However, this phenotype-based approach has yet to be established in vertebrates for probing CM specifically, largely because of the high complexity of colony management.
DNAJB6 belongs to the J protein family and functions as a molecular chaperon that facilitates protein folding and protein assembly (6) (7) (8) . In humans, there are two DNAJB6 protein isoforms that result from alternative splicing of the same gene (9) . While the first 6 exons encode the short cytoplasmic DNAJB6(S), the inclusion of the additional 2 exons at the 3′-end of the cDNA encodes the long nucleic DNAJB6(L). Mutations in DNAJB6(S) were reported to cause limb-girdle muscular dystrophy type 1D (LGMD1D), and DNAJB6(S) has been proposed to ameliorate protein aggregation-induced cytotoxicity in neurodegenerative diseases via its antiaggregation function (10, 11) . In contrast to the more widely studied DNAJB6(S), functions of DNAJB6(L) remains less investigated (12, 13) .
In this study, we report a rapid mutagenesis screening strategy in the vertebrate zebrafish for identificaMutagenesis screening is a powerful forward genetic approach that has been successfully applied in lower-model organisms to discover genetic factors for biological processes. This phenotypebased approach has yet to be established in vertebrates for probing major human diseases, largely because of the complexity of colony management. Herein, we report a rapid strategy for identifying genetic modifiers of cardiomyopathy (CM). Based on the application of doxorubicin stress to zebrafish insertional cardiac (ZIC) mutants, we identified 4 candidate CM-modifying genes, of which 3 have been linked previously to CM. The long isoform of DnaJ (Hsp40) homolog, subfamily B, member 6b (dnajb6b(L)) was identified as a CM susceptibility gene, supported by identification of rare variants in its human ortholog DNAJB6 from CM patients. Mechanistic studies indicated that the deleterious, loss-of-function modifying effects of dnajb6b(L) can be ameliorated by inhibition of ER stress. In contrast, overexpression of dnajb6(L) exerts cardioprotective effects on both fish and mouse CM models. Together, our findings establish a mutagenesis screening strategy that is scalable for systematic identification of genetic modifiers of CM, feasible to suggest therapeutic targets, and expandable to other major human diseases.
tion of CM modifying genes. We identified DNAJB6(L) as a genetic modifier and/or susceptibility gene for human CM, supported by its predominant expression in the cardiac tissues and identification of rare variants in human CM patients. Through both loss-of-function and gain-of-function studies, our results suggest a function of DNAJB6(L) as an ER stress inhibitor, which can be targeted to achieve therapeutic benefits for CM.
Results
Leveraging a gene-breaking transposon-based (GBTbased) insertional mutagenesis screening platform in the scalable zebrafish (Danio rerio) model, we sought to develop a forward genetic approach for discovering CM genes and/or modifiers in a vertebrate (14) . By checking cardiac monomeric red fluorescent protein (mRFP) expression in 609 GBT lines, we were able to identify 44 Zebrafish Insertional Cardiac (ZIC) mutants (Supplemental Table 1 ; supplemental material available online with this article; doi:10.1172/jci. insight.88797DS1) (15) . Having shown cardiac remodeling in adult zebrafish heart upon stress imposed by either anemia or doxorubicin (DOX) injection (16, 17) , we applied DOX stress to these heterozygous ZIC mutants. By using fish survival as a quantifiable index, we demonstrated that GBT0002/sorbs2b, GBT0136/ano5a, and GBT0411/dnajb6b(L) accelerated DOXinduced fish death, and GBT0419/rxraa reduced mortality rates ( Figure 1 and Supplemental Figure 1 ). ANO5 is a known human DCM gene, and studies in mouse and cell culture have previously linked Sorbs2b to CM (18, 19) . Consistent with a salutary modifying effect of GBT419/rxraa, activation of retinoid acid signaling has been shown to attenuate CM in a neonatal cardiomyocyte culture model and a mouse model of diabetes-induced CM (20, 21) . Identification of known CM genes demonstrates the effectiveness of this mutagenesis screening approach.
GBT0411/dnajb6b(L) was further investigated as a potential new CM susceptibility gene or disease modifier. GBT0411 homozygous mutants demonstrated cardiomegaly at 1 year, whereas both heterozygous and homozygous GBT0411 mutants accelerated DOX-induced fish death at only 3 months of age ( Figure  1A and Supplemental Figure 2A ) (15) . At the molecular level, GBT0411 specifically disrupted the long isoform of DnaJ (Hsp40) homolog, subfamily B, member 6b (dnajb6b(L)) ( Figure 1 , B and C). In contrast to a mainly brain-enriched expression of mouse dnajb6 short isoform (dnajb6(S)) (7), zebrafish dnajb6b(L) and both its human and mouse orthologs exhibit previously unrecognized strong cardiac expression (Figure 2 , A-C, and Supplemental Figure 2 , B-D). Cardiomyocyte-specific overexpression of zebrafish dnajb6b(L) rescued the deleterious modifying effects seen in GBT0411 mutants ( Figure 2D and Supplemental Figure 3) , supporting a loss-of-function mechanism for the deleterious modifying effects of dnajb6b(L). Human DNAJB6(L) is reported to localize to the nuclei (12) . We noted perinuclear expression of the zebrafish Dnajb6b(L)-EGFP fusion protein ( Figure 3A) . In both HL-1 cells and mouse heart tissues, the Dnajb6 endogenous protein colocalized well with the nuclear envelope protein Lamin A/C ( Figure 3 , B and C). Dnajb6 could also translocate to the ER on treatment with the ER stress inducer tunicamycin (TN) in an H9c2 cell line, as indicated by partial colocalization with the ER resident protein called glucoseregulated protein 78 (Grp78), a well-established molecular marker for ER stress response ( Figure 3D ) (22) . Consistent with the function of Dnajb6 in the ER stress response, dnajb6b(L) transcripts are upregulated upon TN treatment (Supplemental Figure 4) . In the GBT0411 mutant with disrupted dnajb6b(L), the ER stress level was elevated both at basal level and upon TN treatment, as indicated by Grp78 protein levels ( Figure 3 , E and F). In contrast, a suppressed ER stress level was observed in hearts of transgenic dnajb6b(L) fish upon TN treatment but not of transgenic dnajb6b(S) fish. Together, these data characterize a function of dnajb6b(L) as an ER stress inhibitor.
Response to ER stress, also called unfolded protein response, is commonly known as a condition when the ER lumen is overloaded with unfolded or misfolded proteins. It has been implicated as a pathologic event in CM and heart failure (23) . We tested the hypothesis that ER stress is a major pathologic event in DOXinduced CM and could serve as a target to ameliorate the deleterious modifying effects of GBT0411. Indeed, we detected late onset activation of ER stress in DOX-injected zebrafish ( Figure 4A ). Whereas ER stress is further activated in the GBT0411 mutant, its activation is suppressed by the cardiac-specific dnajb6b(L) transgene ( Figure 4B ). Consistent with the cardioprotective effects of sodium phenylbutyrate (PBA), a chemical chaperone that inhibits ER stress in DOX-induced cardiac dysfunction in mice (24), we found that PBA treatment could decrease the fish mortality rate in both WT and GBT0411 mutant after DOX injection ( Figure 4C ).
The identification of Dnajb6b(L) as a negative regulator of ER stress and the therapeutic effects of ER stress inhibition through PBA treatment prompted us to test Dnajb6b(L) as a potential therapeutic target for CM. This hypothesis was supported by our observation in zebrafish, where overexpression of dnajb6b(L) in cardiomyocytes reduced the mortality rate in anemia-induced CM (Supplemental Figure 5 ). To test the cardioprotective function of Dnajb6(L) in mammals, we used the adeno-associated virus serotype 9 (AAV9) medicated gene delivery system (25) . Robust ectopic expression of Dnajb6(L) in mouse heart was detected ( Figure 5 , A and B). To assess the impact on CM development, DOX at 12 mg/kg body weight was i.p. injected 1 month after AAV9-Dnajb6(L) preinjection. The PBS-injected mice showed a severe mortality rate, with the surviving animals showing markedly reduced cardiac function at 3 months after DOX injection. By comparison, the majority of the mice preinjected with AAV9-Dnajb6b(L) survived with well-preserved heart function ( Figure 5 , C and D, and Table 1 ). Persistent elevation of ER stress was noted in hearts from PBS but not from AAV9-Dnajb6(L) preinjected mice ( Figure 5B ). Pathologic events such as cardiomyocyte vacuolization and loss of myofibril structural integrity found in PBS-injected mice were largely absent in the AAV9-Dnajb6b(L) preinjected mice ( Figure 5E ). Together, these data suggest that Dnajb6(L) overexpression is cardioprotective on DOX-induced CM in mammals.
To seek direct evidence for DNAJB6 as a genetic factor for CM, we performed genetic mutational analysis of the translated sequence of DNAJB6 in DNA of human CM patients for possible disease association. We Table  2 ). We pursued the 3 variants located in the C-terminal domain, which solely affect the DNAJB6(L) isoform -2 identified in patients with DCM (A296R and S316W) and 1 in a patient with HCM (S321L). In vivo functional analysis in zebrafish embryonic system revealed that the DNAJB6(L)-S316W variant exhibited faster protein turnover and a slower migration rate than WT DNAJB6(L), while the p.A296R and p.S321L variants showed no difference ( Figure 6 , B and C). Transient overexpression of DNAJB6(L)-S316W, but not the DNAJB6(L) WT and p.A296R and p.S321L variants, led to activation of Grp78 protein and transcriptional activation of ER stress markers ( Figure 6 , D and E) (22, 26) . Similarly, stable overexpression of DNAJB6(L)-S316W in a transgenic line in adult zebrafish resulted in elevated ER stress upon ER stress inducer TN treatment and accelerated the transgenic fish mortality rate after DOX injection (Figure 6 , F and G). Together, the rare sequence variants identified in human patients implicate DNAJB6(L) as a CM susceptibility gene, supported by in vivo evidence of aberrant ER stress activation for the DCM-associated S316W variant.
Discussion
In summary, our data identified DNAJB6(L) as a cardiac isoform that might function as a CM modifier. In contrast, previous reports mostly focused on the functional study of DNAJB6(S) in neurodegenerative disease and LGMD1D (8, 10, 11) , while the function of DNAJB6B(L) was less investigated (12, 13) . Our present study further suggested that DNAJB6(L), but not DNAJB6(S), might function as an ER stress inhibitor. The differential subcellular localization of these 2 isoforms must contribute to their different effects. Because these 2 isoforms share their N-terminal sequences, it is plausible that the C-terminal amino acids unique to either isoform are key regions that govern their different effects. Our studies in the heart strongly suggest that these functions of DNAJB6(L) need to be investigated in diseases affecting other organs, including neurological disorders and muscular dystrophy. Our mechanistic studies of DNAJB6(L) have clear clinical implications. First, ER stress inhibition might be an effective strategy to protect the rare case of a patient with DNAJB6-mediated DCM or, more importantly and more commonly, cancer patients treated with DOX. Because the drug PBA is approved by the US FDA (27) , future studies to repurpose PBA to these patient groups are warranted. An immediate future study will be to generate S316W transgenic or knock-in mice, which will allow us to test whether its susceptibility to DOX-induced cardio toxicity is conserved in mammals and whether PBA administration is cardioprotective. Second, our results that AAV9-mediated overexpression of Dnajb6(L) exhibited a cardioprotective effect on mice indicated that DNAJB6(L) could be further pursued as a therapeutic target for human CM and heart failure.
Taken together, we present a rapid mutagenesis screening strategy in an in vivo vertebrate animal model for effective identification of genetic modifiers and potential therapeutic targets for human CM. Of note, our current screen focuses on DOX-induced CM because of its efficiency and throughput for an initial mutagenesis screening method. An obvious future direction is to determine whether genetic modifiers and therapeutic strategies identified herein are applicable to other types of CM. Nevertheless, because this approach is scalable to cover the entire genome with reasonable cost, we anticipated that our strategy will facilitate the generation of a comprehensive genetic landscape of CM, serving to advance the capacity to interpret individual genomes for diagnosis, prognosis, and individualized therapy for CM.
Methods
Animals. Zebrafish (Danio rerio) WIK were maintained under a 14 hours light/10 hours dark cycle at 28.5°C. WT C57BL/6 male mice (age, 8 weeks) were purchased from the Jackson Laboratory and maintained on a 12-hour light-dark cycle and were inspected daily.
Expansion of ZIC mutant collection and DOX modifier screen. We previously developed an expression-based strategy to enrich ZIC mutants from GBT lines (15) . In the present study, we expanded the ZIC mutant collection by identifying GBT lines with visible mRFP signal in the heart during either embryonic or adult Western blot (upper) and quantification (lower) analysis of Grp78 protein levels at 2 months after DOX injection in indicated mutants and/ or double-transgenic fish hearts. Grp78 protein level was further elevated in the GBT0411 mutant fish heart after DOX injection. Cardiomyocyte-specific overexpression of dnajb6b(L) inhibited the elevated ER stress in the GBT0411 mutant fish heart at 2 months after DOX injection. Values are expressed relative to WT controls. Data represent mean ±SEM; 1-way ANOVA comparisons, *P < 0.05. (C) KaplanMeier survival curves of indicated adult fish injected with a single bolus of 20 μg/ gbm DOX with or without incubation with sodium phenylbutyrate (PBA), a chemical chaperone of ER stress inhibitor (250 μM, 10 hours/day, 5 days/week for the entire experiment). PBA administration protected against DOX-induced fish death in both WT and the GBT0411 mutant. *P < 0.05, log-rank test.
stages. To examine cardiac expression during embryonic stages, we anesthetized embryos 2-5 days postfertilization (dpf) using 0.16 mg/ml tricaine (Argent Chemical Laboratories) to arrest the heartbeat. mRFP signal was observed using a Zeiss microscope. To examine cardiac expression at adult stages, fish 3-18 months of age were anesthetized with tricaine (Argent Chemical Laboratories). Hearts were dissected and observed under a Zeiss microscope. To perform the DOX screen, 10-25 fish for each ZIC mutant at 3-12 months of age were i.p. injected with a single dose at 20 μg/g body weight of DOX dissolved in 5 μl Hank's buffer using a NanoFil 10-μl syringe (World Precision Instruments Inc). Fish survival was monitored daily for 2-4 months after DOX injection.
Northern blotting. Northern blot hybridization was performed with the NorthernMax-Gly kit (Ambion) following the manufacturer's instructions. Briefly, approximately 1 μg of total RNA was isolated from zebrafish hearts (6 months old) or C57BL/6 male mice hearts (8 weeks old) using the TRIzol reagent (Thermo Fisher Scientific). 32 P-labeled RNA probes that bind to the N-terminal common region of both dnajb6(S) and dnajb6(L) isoforms were synthesized from 100-ng fish or mouse cDNA fragments using a random primed DNA labeling kit (Roche Diagnostics). The primers for amplifying the zebrafish dnajb6b cDNA are forward 5′ GGATTATTACCACATCCTTGGTG 3′ and reverse 5′ GCTGTCCAGTCGGAG- Generation of transgenic fish lines. Zebrafish dnajb6b(S) and dnajb6b(L) cDNAs were amplified with total RNA isolated from zebrafish heart tissue through reverse transcriptase PCR (RT-PCR) using 2 primer pairs: forward 5′ TAGCGGATCCGCCACCATGGAGGAGGATTATTACCACATCCTTG-GTG 3′ and reverse 5′ AGCTCTCGAGAACCACACCCCAATCCGGGGAGTGAGTCTT 3′ and forward 5′ TAGCGGATCCGCCACCATGGAGGAGGATTATTACCACATCCTTGGTG 3′ and reverse 5 AGCTCTCGAGCATTTGCTGTCCAGTCGGAGTAACTGC 3′. Human DNAJB6(L) WT and DNAJB6(L) p.S316W cDNAs were amplified through PCR using the forward primer 5′ ATCGGGATCC-GCCACCATGGTGGATTACTATGAAGTTCTAGG 3′ and reverse primer 5′ ACTGCTCGAGCAGT-GATTGCCTTTGGTCGACTTCTT 3′ using human pCS2-DNAJB6(L) WT or pCS2-DNAJB6(L) p. S316W as a template, respectively.
The resulting PCR fragments were digested with BamH I and XhoI and then cloned into pENTRI1a to generate pENTRI-dnajb6b(S), pENTRI-dnajb6b(L), pENTRI-DNAJB6(L) WT, and pENTRI-DNAJB6(L) p.S316W. The final constructs for fish dnajb6b(S) and dnajb6b(L) were generated through a recombination reaction among p5E-cmlc2 (15), pENTRI1a with corresponding cDNAs, p3E-EGFP-polyA, and pDestTol2pA destination vector that is facilitated by the Gateway LR clonase II plus enzyme (Thermo Fisher Scientific). For the human DNAJB6(L) WT and p.S316W variant, we used the p5E-ttna plasmid containing ttna enhancer. Subsequently, 50 ng of the resulting final plasmid was coinjected with 100 ng of transposase mRNA into single-cell-staged WT WIK embryos to generate stable transgenic lines.
Cell culture and antibody staining. The HL-1 myocytes, a cardiac muscle cell line derived from adult mouse atrium, were maintained in Complete Claycomb Medium (Sigma Aldrich) supplemented with 100 μM norepinephrine, 4 mM L-glutamine (Sigma Aldrich), and 10% FBS (Sigma Aldrich). The myocytes were cultured in flasks coated with 12.5 μg/ml fibronectin and 0.02% gelatin (both Sigma Aldrich). The H9c2 cells, rat heart-derived embryonic myocytes (American Type Culture Collection), were cultured in DMEM (Thermo Fisher Scientific) with 4 mM/l glutamine, 4.5 g/l glucose, 1.0 mM sodium pyruvate, and 10% FBS at 37°C in 5% CO 2 . For antibody staining in HL-1 and H9c2 cells, the cultured cells with or without TN treatment (1 μg/ml for 24 hours) were subjected to antibody staining using previously described methods (16) . Briefly, cells were fixed in 4% PBS-buffered formaldehyde for 10 minutes, followed by incubation with the primary antibodies anti-DNAJB6 (1:200, Novus Biologicals LLC, catalog H00010049-M01), anti-Lamin A/C (1:200, Santa Cruz Biotechnology Inc., catalog sc-6215), and anti-GRP78 (1:200, Novus Biologicals LLC, catalog NBP-06274) for 2 hours at room temperature. Next, samples were washed in PBS and incubated with secondary antibodies for 30 minutes at room temperature, followed by PBS wash. For immunostaining in the mouse heart tissue, the left ventricle of 8-week-old WT C57BL/6 mice hearts were dissected, and frozen 8-μm sections were fixed with ice cold acetone followed by the staining protocol described above. The anti-Dnajb6 (1:100, Santa Cruz Biotechnology Inc., catalog sc-104204) and antiLamin A/C (1:200, Cell Signaling Technolgoy, catalog 4777) were used. All images were captured using a Zeiss Axioplan II microscope equipped with ApoTome and AxioVision software (Carl Zeiss Microscopy).
Western blotting. Human heart and skeletal muscle tissue lysates were purchased from Novus Biologicals LLC. Tissues harvested from overdose anesthesia-treated mice or zebrafish were transferred immediately to RIPA buffer (Sigma Aldrich) supplemented with complete protease inhibitor cocktail (Roche Diagnostics) and homogenized using a Bullet Blender tissue homogenizer (Next Advance Inc.). Resultant protein extracts were subjected to Western blotting using a standard protocol. The following primary antibodies were used: anti-actin (1:4,000, Santa Cruz Biotechnology Inc., catalog sc-1615), anti-DNAJB6 (1:6,000, Abcam, catalog ab198995 ), anti-GAPDH (1:8,000, Santa Cruz Biotechnology Inc., catalog sc-25778), anti-GRP78 (1:2,000, Novus Biologicals LLC, catalog NBP-06274), anti-Chop (1:1,000, Abcam, catalog ab11419), and an anti-GFP antibody (1:10,000, Torrey Pines Biolabs Inc., catalog TP401).
Quantitative PCR. To determine the relative expression level of ER stress molecular markers grp78 and chop, we performed quantitative PCR (qPCR) as previously described (15) . gapdh was used as an internal control to normalize expression levels. The following primers were used: grp78 forward 5′ TCAGCGTCAGGCCAC-TAA 3′, grp78 reverse 5 GTCAGCAGAGACACGTCAAA 3′; chop forward 5′ CGGTTCCCGACACAT-CA 3′, and chop reverse 5′ CACTTTCCTTTCATTCTCCTGTT 3′. qPCR was also carried out to determine the transcriptional induction of dnajb6b gene on treatment with the ER stress inducer TN. dnajb6a was also included. The primers for dnajb6b(L) were forward 5′ ACACAACCGATACCTCCGAAACGT 3′ and reverse 5′ GCTTCTTTTTGGTGTCTGACTCCTTC 3′; for dnajb6b(S), forward primer 5′AAGGAGCAGTTACTC-CGACTGG 3′ and reverse primer 5′ AGACTTCACCCTGTTTACCTCTGC 3′; and for the dnajb6a gene, forward primer 5′ CACATTCCGCAATCCAGAG 3′ and reverse 5′ AAATCCCGCACCAAAAGG 3′. To quantify the percent-native transcript of a tagged gene in corresponding GBT mutants, each heart was dissected from adult zebrafish at 3-6 months of age. qPCR was performed using a previously described method (15) . The following primers were used: GBT0002/sorbs2b forward 5′ AACTTCTCCAGTGCCAAGCAAAGC 3′ and reverse 5′ CCAGGCATTAGGACTGAAAGTAGGCA 3′; GBT0136/ano5a forward 5′ GGCACTGGA-GATCAGATCAC 3′ and reverse 5′AAGTTGAAACGTCTCCTTATCC 3′; GBT0411/dnajb6b(L) forward 5′ CCTCCATTTCCACATCCACCA 3′ and reverse 5′ CCTTTTCTGAAGGGTTCTGGGC 3′; and GBT0419/ rxraa forward 5′ TGGAAACCAAACCTTTCTTGTC 3′ and reverse 5′ CTGTAGAAAGCCTGCGTTG 3′.
Whole-mount in situ hybridization. Digoxigenin-labeled probes were generated from PCR products using T7 promoter-tagged primer pairs. The dnajb6b(S) and dnajb6b(L) isoform-specific primers were used: dnajb6b(S) forward 5′ CAGTGAATCGCAGAGGTAAACAG 3′ and reverse 5′ GGTAATACGACTCAC-TATAGGGTGCAGCATTCAAAACAGGTG 3′; and dnajb6b(L) forward 5′ ACACAACCGATACCTC-CGAAACGT 3′ and reverse 5′ GGTAATACGACTCACTATAGG GAACCACACCCCAATCC-GGGGAGTGAGTCTT 3′. Whole-mount in situ hybridization procedures were subsequently performed as described previously (15) .
Mouse AAV9-Dnajb6(S) and (L) virus and DOX injection.
To produce mouse AAV9-Dnajb6(L) virus, total RNA was extracted from C57BL/6 mice heart tissue using TRIzol reagent (Thermo Fisher Scientific). After purification with the RNeasy Plus kits (QIAGEN), 1 μg resultant total RNA was used to synthesize cDNAs with a SuperScript III First-Strand Synthesis SuperMix (Thermo Fisher Scientific). Mouse Dnajb6(L) cDNAs were PCR amplified using Expand High-Fidelity PCR System (Roche Diagnostics) with the primers Dnajb6(L) forward 5′ ATCGGGATCCGCCACCATGGTGGATTACTATGAAGT-GCTGGGCG 3′ and reverse 5′ ACTGGGATCC CTAATGGTTCCCTTTGGTCGACTTCTTCTTC 3′. The resultant RT-PCR products were subcloned into the pAAV-MCS vector backbone (Stratagene Corp.) after BamH I enzyme digestion. The cDNA fragment was under the transcriptional control of the cytomegalovirus promoter and hGH polyA sequence. Clones with correct insertional direction were identified by direct sequencing. The production of recombinant AAV9 was carried out as described previously (25) . Briefly, AAV vectors were generated by packaging AAV2-based recombinant genomes in AAV9 capsids. The production of these pseudotyped AAV2/9 vectors (AAV9) was performed by triple transfection using an adenovirus-free system (Agilent Technologies). Next, 5 × 10 11 genomic copy of virus diluted in 100
μl PBS was injected into mice via tail vein. One month after the AAV9 injection, the first echocardiography was conducted to determine the baseline before DOX injection, and DOX at a dose of 12 mg/kg body weight was dissolved in 200 μl saline and i.p. injected into C57/B6 male mice (8 weeks old) using a 28-gauge 1/2-inch insulin syringe (BD Biosciences). Three months after the DOX and 4 months after the AAV9 injection, the second echocardiography was carried out. Heart tissues were then harvested for subsequent histology and protein expression analysis. Echocardiography in mice. Mice were anesthetized under light isoflurane (0.5%-1.0% v/v) administered via a nose cone. Echocardiography gel was placed on the shaved chest, and the mouse heart was imaged with a 13-MHz probe using 2-dimensional echocardiography (GE Healthcare). All measurements were made by an operator to whom the study groups were masked.
H&E staining. To harvest tissues from mice, ventilation was ceased and mice were euthanized by administration of high-dose (5%) isoflurane anesthesia. Dissected mice heart left ventricles were immediately fixed in 4% PBS buffered formaldehyde overnight at 4°C and sent to the Mayo Clinic Histology Core Laboratory for sample process and H&E staining.
Electron microscopy. For transmission electron microscopy analysis, the left ventricle apexes of dissected mice were fixed immediately in Trump's solution (4% paraformaldehyde and 1% glutaraldehyde in 0.1 M phosphate buffer [pH 7.2]) at room temperature for 1 hour, followed by overnight incubation at 4°C. Fixed samples were subsequently processed and imaged at the Mayo Clinic Electron Microscopy Core Facility using a Philips CM10 transmission electron microscope.
Identification of DNAJB6 variants in human patients with idiopathic DCM from Mayo Clinic. Patients were clinically evaluated at Mayo Clinic, and phenotypic characterization of idiopathic DCM was based on echocardiographic measurements. Diagnostic criteria for DCM were left ventricular diastolic dimension, systolic dimension, or both; >95th percentile indexed for body surface area; and left ventricular ejection fraction <50%. Genomic DNA was isolated from peripheral blood white cells or saliva. For DNAJB6 mutation scanning and Sanger sequencing, genomic DNA samples from 214 unrelated probands with DCM were used. PCR primer pairs were designed to amplify the 9 translated exons of DNAJB6 (NM_058246.3). PCR products from 6 of the 9 translated exons (exons 2-7) were analyzed with denaturing high-performance liquid chromatography (DHPLC) heteroduplex analysis (WAVE DHPLC System; Transgenomic Inc.). Chromatograms of amplified and heteroduplexed products were analyzed against the WT pattern. Abnormal traces were Sanger sequenced to determine the precise genetic variants. Because of special interest in the DNAJB6 long isoform and its isoform-specific exons, all DCM probands underwent Sanger sequencing for exons [8] [9] [10] .
Identification of DNAJB6 variants in human patients with HCM from Mayo Clinic. Patients were clinically evaluated at Mayo Clinic, and phenotypic characterization of HCM in patients and family members was based on echocardiographic measurements. Diagnostic criterion for HCM was a left ventricular wall thickness >13 mm in the absence of any other conditions that could cause cardiac hypertrophy, such as hypertension or aortic stenosis. Genomic DNA was isolated from peripheral blood white cells. For DNAJB6 mutation scanning and Sanger sequencing, we used genomic DNA samples from 86 unrelated probands with heretofore genetically elusive HCM having been analyzed previously for mutations in the 10 most common HCM susceptibility genes. For mutation scanning and Sanger sequencing, PCR primer pairs were designed to amplify the 9 translated exons of DNAJB6 (NM_058246.3). PCR products from 6 of the 9 translated exons were analyzed by DHPLC (WAVE DHPLC System; Transgenomic Inc.). Chromatograms of amplified and heteroduplexed products were analyzed against the WT pattern. Abnormal traces were Sanger sequenced to determine the precise genetic variants.
Identification of a DNAJB6 variant in human patients with idiopathic DCM and HCM from China. Seventeen DCM patients, 8 HCM patients, and 23 controls were recruited from the Han Chinese population. The diagnosis of DCM was based on echocardiographic measurements according to WHO criteria. Enrichment of DNAJB6 genomic sequences was performed with genomic DNA templates using the Access Array System (Fluidigm) for Ion Torrent PGM (personal genome machine) according to the manufacturer's instructions. Each sample DNA was combined with primer pairs in a microfluidic chip. The chip was loaded with PCR reagents and transferred to a thermocycler. Sample barcodes and sequence indexes and sequencing adaptors were attached with a second-step PCR reaction. Deep sequencing was conducted using Ion OneTouch 200 (Thermo Fisher Scientific) reagent kits, Ion PGM Sequencing 200 Kit (Thermo Fisher Scientific), and 318 scale chips. We use the Ion Torrent Suite 3.2 package for sequence analysis and variant calling. Primers were trimmed and variants called with a variant frequency threshold at 25%. The Integrative Genomics Viewer was used for visualization. To validate candidate variants, the targeted region was amplified by PCR using a 96-well GeneAmp PCR System 9700 (Applied Biosystems). GRCh37/hg19 was used as the reference sequence. From each sample, 10 ng DNA was used as a template, together with the 2X Taq PCR Master Mix (Lifefeng Biotech). Sequencing was conducted using a 3730xl DNA Analyzer (Applied Biosystems), a capillary-based Sanger sequencing machine.
Frequency of all 5 identified variants in the population were obtained from online variant and exome databases, such as dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), 1000 genome project (http://browser.1000genomes. org/index.html), Exome Sequencing Project (http://evs.gs.washington.edu/EVS/), and Exome Aggregation Consortium (http://exac.broadinstitute.org/).
Transient embryonic expression of human DNAJB6(S) and DNAJB6(L) WT and 3 DNAJB6(L) variants. DNAJB6(S)
cDNA was PCR amplified from pEGFP-N1-MRJ(S)-GFP (12) using Expand High-Fidelity PCR System (Roche Diagnostics). The following primers were used: DNAJB6(S/L) forward 5′ ACTGGGATCC-GCC ACCATGGTGGATTACTATGAAGTTCTAGG 3′ and DNAJB6(S) reverse 5′ACTGGGATC CTT-GTTATCCAAGCGCAGCAGCTGCTC 3′. DNAJB6(L) cDNA was PCR amplified from MGC human DNAJB6 sequence-verified cDNA (Dharmacon, GE Healthcare; catalog MHS6278-202827593) as a template. The sequences of the primers are DNAJB6(S/L) forward 5′ ACTGGGATCCGCC ACCATGGTG-GATTACTATGAAGTTCTAGG 3′ and DNAJB6(L) reverse 5′ ACTGGGATCGTGATTGCCTTTGGTC-GACTTCTT 3′. The resultant PCR products were digested with BamH I and cloned into the pCS2 + GFP (28) vector to generate pCS2-DNAJB6(S) and pCS2-DNAJB6(L), respectively. GeneArt Site-Directed Mutagenesis System (Invitrogen, catalog A13282) was used to generate 3 DNAJB6(L) variants -DNAJB6(L) p. A296R, DNAJB6(L) p.S316W, and DNAJB6(L) p.S321L -using the pCS2-DNAJB6(L) as a template. The following primers were used: forward 5′ GCCCTGGGACCCC CTCAGGTCCGCAGCAGGATTG 3′ and reverse
